Amgen is delighted to announce the launch of the

PCSK9 Competitive Grant Program

, lo que brindará una oportunidad para que los investigadores de todo el mundo compitan por subvenciones individuales de hasta 200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.

The program is global in reach and is open to proposals from established and junior investigators*.

The deadline for applications is Friday, Mayo 11, 2018 (11:59 pm US Pacific Time).

*Junior investigators should be within 5 years of completion of training

 

Categorías: Stem Cells terapia

NBScience

organización de contratos de investigación

terapia con células madre